CD27 | CD27 molecule | Cancer-related genes CD markers Disease related genes Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CD37 | CD37 molecule | CD markers Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CD3E | CD3e molecule, epsilon (CD3-TCR complex) | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
CD48 | CD48 molecule | CD markers Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD5 | CD5 molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD69 | CD69 molecule | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
CD79A | CD79a molecule, immunoglobulin-associated alpha | Cancer-related genes CD markers Disease related genes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CDC25C | Cell division cycle 25C | Cancer-related genes Enzymes Predicted intracellular proteins
| | | | | Tissue enhanced |
CDH15 | Cadherin 15, type 1, M-cadherin (myotubule) | Disease related genes Predicted membrane proteins
| | | | | Tissue enriched |
CDH2 | Cadherin 2, type 1, N-cadherin (neuronal) | CD markers Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CDX2 | Caudal type homeobox 2 | Cancer-related genes Predicted intracellular proteins Transcription factors
| | | | | Group enriched |
CEACAM5 | Carcinoembryonic antigen-related cell adhesion molecule 5 | Cancer-related genes CD markers Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CHGA | Chromogranin A (parathyroid secretory protein 1) | Cancer-related genes Candidate cardiovascular disease genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CKAP2L | Cytoskeleton associated protein 2-like | Predicted intracellular proteins
| | | | | Tissue enhanced |
CLC | Charcot-Leyden crystal galectin | Predicted intracellular proteins
| | | | | Tissue enriched |
CLDN16 | Claudin 16 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
CMTM5 | CKLF-like MARVEL transmembrane domain containing 5 | Predicted membrane proteins
| | | | | Tissue enriched |
CNDP1 | Carnosine dipeptidase 1 (metallopeptidase M20 family) | Enzymes Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Group enriched |
CNTRL | Centriolin | Cancer-related genes Disease related genes Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
COL4A2 | Collagen, type IV, alpha 2 | Cancer-related genes Disease related genes Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
COLEC12 | Collectin sub-family member 12 | Predicted membrane proteins
| | | | | Tissue enhanced |
CSTA | Cystatin A (stefin A) | Cancer-related genes Disease related genes Plasma proteins Predicted intracellular proteins
| | | | | Group enriched |
CTAG1A | Cancer/testis antigen 1A | Cancer-related genes Predicted intracellular proteins
| | | | | Tissue enriched |
CTSG | Cathepsin G | Enzymes Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
CTSW | Cathepsin W | Enzymes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CXorf67 | Chromosome X open reading frame 67 | Predicted intracellular proteins
| | | | | Group enriched |
DBH | Dopamine beta-hydroxylase (dopamine beta-monooxygenase) | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enriched |
DCT | Dopachrome tautomerase | Enzymes Predicted membrane proteins
| | | | | Tissue enriched |
DCUN1D1 | DCN1, defective in cullin neddylation 1, domain containing 1 | Predicted intracellular proteins
| | | | | Tissue enriched |
DIAPH3 | Diaphanous-related formin 3 | Cancer-related genes Disease related genes Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
DNASE1 | Deoxyribonuclease I | Disease related genes Enzymes Potential drug targets Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
DNM1 | Dynamin 1 | Enzymes Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
DPYSL3 | Dihydropyrimidinase-like 3 | Predicted intracellular proteins
| | | | | Tissue enhanced |
DSC3 | Desmocollin 3 | Disease related genes Plasma proteins Predicted membrane proteins
| | | | | Group enriched |
DSP | Desmoplakin | Cytoskeleton related proteins Disease related genes Plasma proteins Predicted intracellular proteins
| | | | | Group enriched |
DUSP9 | Dual specificity phosphatase 9 | Enzymes Predicted intracellular proteins
| | | | | Group enriched |
EBI3 | Epstein-Barr virus induced 3 | Predicted secreted proteins
| | | | | Tissue enriched |
EGFR | Epidermal growth factor receptor | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
EHD2 | EH-domain containing 2 | Predicted intracellular proteins
| | | | | Tissue enhanced |
ELAVL2 | ELAV like neuron-specific RNA binding protein 2 | Predicted intracellular proteins
| | | | | Group enriched |
ENPP1 | Ectonucleotide pyrophosphatase/phosphodiesterase 1 | CD markers Disease related genes Enzymes Potential drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
EPHA2 | EPH receptor A2 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins RAS pathway related proteins
| | | | | Tissue enhanced |
ESR1 | Estrogen receptor 1 | Cancer-related genes Disease related genes FDA approved drug targets Nuclear receptors Predicted intracellular proteins Transcription factors
| | | | | Group enriched |
F2 | Coagulation factor II (thrombin) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enriched |
FABP4 | Fatty acid binding protein 4, adipocyte | Cancer-related genes Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
FABP5 | Fatty acid binding protein 5 (psoriasis-associated) | Cancer-related genes Plasma proteins Predicted intracellular proteins Transporters
| | | | | Tissue enriched |
FASN | Fatty acid synthase | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
FCER2 | Fc fragment of IgE, low affinity II, receptor for (CD23) | Cancer-related genes CD markers Predicted intracellular proteins Predicted membrane proteins
| | | | | Group enriched |
FCN1 | Ficolin (collagen/fibrinogen domain containing) 1 | Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
FDXR | Ferredoxin reductase | Enzymes Mitochondrial proteins Predicted intracellular proteins
| | | | | Tissue enhanced |